1. Home
  2. LXFR vs SLN Comparison

LXFR vs SLN Comparison

Compare LXFR & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LXFR
  • SLN
  • Stock Information
  • Founded
  • LXFR 1898
  • SLN 1994
  • Country
  • LXFR United States
  • SLN United Kingdom
  • Employees
  • LXFR N/A
  • SLN N/A
  • Industry
  • LXFR Major Chemicals
  • SLN Biotechnology: Pharmaceutical Preparations
  • Sector
  • LXFR Industrials
  • SLN Health Care
  • Exchange
  • LXFR Nasdaq
  • SLN Nasdaq
  • Market Cap
  • LXFR 335.4M
  • SLN 299.4M
  • IPO Year
  • LXFR 2012
  • SLN N/A
  • Fundamental
  • Price
  • LXFR $13.42
  • SLN $4.81
  • Analyst Decision
  • LXFR
  • SLN Buy
  • Analyst Count
  • LXFR 0
  • SLN 5
  • Target Price
  • LXFR N/A
  • SLN $32.60
  • AVG Volume (30 Days)
  • LXFR 135.6K
  • SLN 61.8K
  • Earning Date
  • LXFR 10-28-2025
  • SLN 08-07-2025
  • Dividend Yield
  • LXFR 3.87%
  • SLN N/A
  • EPS Growth
  • LXFR N/A
  • SLN N/A
  • EPS
  • LXFR 0.90
  • SLN N/A
  • Revenue
  • LXFR $403,800,000.00
  • SLN $27,169,000.00
  • Revenue This Year
  • LXFR $3.12
  • SLN N/A
  • Revenue Next Year
  • LXFR $3.31
  • SLN N/A
  • P/E Ratio
  • LXFR $13.74
  • SLN N/A
  • Revenue Growth
  • LXFR 5.60
  • SLN 22.28
  • 52 Week Low
  • LXFR $9.41
  • SLN $1.97
  • 52 Week High
  • LXFR $15.64
  • SLN $20.48
  • Technical
  • Relative Strength Index (RSI)
  • LXFR 64.00
  • SLN 34.88
  • Support Level
  • LXFR $12.32
  • SLN $4.91
  • Resistance Level
  • LXFR $13.86
  • SLN $5.34
  • Average True Range (ATR)
  • LXFR 0.45
  • SLN 0.48
  • MACD
  • LXFR 0.11
  • SLN -0.05
  • Stochastic Oscillator
  • LXFR 78.85
  • SLN 0.71

About LXFR Luxfer Holdings PLC

Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: